The third phase of the vaccine trial aims to recruit 1,500 participants in northern Colorado.
Denver — UCHealth announced on Thursday that researchers in northern Colorado are recruiting participants for a study that will test COVID-19 vaccine candidates.
The study is the second vaccine trial launched by UCHealth and aims to recruit 1,500 participants in northern Colorado. There will be more than 30,000 volunteers participating in the experiment nationwide.
The two COVID-1
According to UCHealth, those who participated in the trial were 18 years of age and above, and because of their working environment or habits, they have a higher risk of exposure. This higher-risk group will include occupations such as health care workers, teachers, first responders, or grocery store workers. Eligible participants may also have stable health, putting them at risk of contracting COVID-19 or serious illnesses due to the disease.
The principal, Dr. Gary Luckasen, said: “This will allow us to have a large group of people who will receive the vaccine or placebo vaccine to see if it is really effective in a few weeks, months to up to two years.” Trial investigator and medical director of UCHealth’s clinical research program in northern Colorado. “The size of the team is very important because we can get a lot of information about viruses, vaccines and how they interact.”
>Video above: So far, the development of the COVID-19 vaccine has not been affected by the virus mutation
UCHealth said the candidate vaccine was developed by Oxford University and the pharmaceutical company AstraZeneca.
The results of the initial phase of research on this particular vaccine have recently been released, indicating that the vaccine has produced an antibody response. According to the report, most participants had neutralizing antibodies after one dose, while all participants had antibodies after two doses.
UCHealth said in a press release that, unlike traditional vaccines, which expose people to a small amount of the virus, the vaccine is an inactive cold virus-adenovirus-that binds to a protein visible on the outside of the SARS-CoV-2 coronavirus.
Lucasson said: “In theory, this sounds good.” “The question is how much resistance it will cause, and is it enough to prevent the spread of the virus in the future?”
“We have conducted major clinical trials that affect heart valves and patients who have suffered severe trauma or battling cancer. This is a very impressive and important study, especially for those who are affected or may one day be affected. Words.” Lucasson said. “This COVID vaccine research is a bit different. COVID-19 absolutely affects everyone now, and everyone wants to return to a more normal life. If we can develop a successful vaccine, then the faster we do it, the better it will be for everyone. The better.”
UCHealth patient records can identify some of the 1,500 Colorado participants who participated in the Phase III study and invite them to participate. UCHealth said that other people interested in participating can answer pre-screening questions online to see if they meet the conditions.
Dr. Diana Breyer said: “All vaccines are slightly different from each other, so the current trials conducted on a global scale are crucial to determine which method is most effective against COVID-19. Yes.” is the chief quality officer of UCHealth’s facility in northern Colorado. “Being selected for this groundbreaking research is a real testament to our research program expertise and our experience as a system and working with partners to push the boundaries of innovation to improve care and outcomes.”
Those interested in participating should visit bit.ly/NoCoVaccineStudy for more information and to see if they are eligible.
Suggested video: COVID-19 Coronavirus